Validate your hypotheses, narrow your target or biomarker panels, de-risk your trials — by running on real external patient cohorts from hospitals and biobanks.
No data transfer required. Ethically compliant. Full protection for data and models.
The problem
Hospitals sit on deeply characterized patient cohorts — multi-omics, longitudinal follow-up, genetically confirmed diagnoses. But governance, privacy regulation, and IT complexity mean pharma cannot access the data directly. Data licensing negotiations take months. Building your own cohort takes years.
Biomarker panels validated in one population fail to translate to another. Without running your own analytics on an independent cohort, you're designing trials on assumptions.
In rare disease, finding patients is already hard. Setting an inclusion criterion wrong — a lab value cutoff that excludes 40% of eligible patients — blocks recruitment entirely. Without real-world distributions from an independent cohort, trial design is guesswork.
tracebloc removes the bottleneck. Your analytics travel to the data. Patient data stays at the hospital. You get results in weeks, not quarters.
How It Works
Patient data never leaves the hospital. You send your candidates and model specifications — we return aggregate results only.



The Platform
Select a cohort, configure your analysis, and review ranked results — all without patient data ever leaving the hospital environment.
Use cases
Each scenario maps to how pharma actually acquires and validates clinical data — shaped by conversations with clinical genomics leads, bioinformatics heads, and commercial teams.
The data
Whole genome sequencing, bulk + single-cell RNA-seq, proteomics, and metabolomics – all on the same patients.
Structured ontology mappings (HPO, SNOMED-CT, LOINC) across medical histories, doctor's letters, and clinical lab routines.
Multiple visits per patient capturing disease progression and treatment response directly — not a single snapshot.
Full multi-omics coverage on age-matched healthy controls for clean baseline comparisons across all analyses.
Genetic ground truth across multiple rare disease groups removes diagnostic ambiguity from model training.
Data stays at the hospital. Algorithms travel to the data. You receive aggregate statistics, ranked panels, and performance metrics only.
Why Trust This
All datasets originate from registered clinical studies at leading European university hospitals — with formal ethics approval, structured consent, and research-grade phenotyping. Not scraped, not aggregated — clinically collected under protocol.
Connected to a growing network of leading university hospitals across Europe — providing the infrastructure for scaling cohorts across populations, therapeutic areas, and geographies.

Every workflow on this platform was validated through conversations with clinical genomics leads, bioinformatics heads, and commercial teams at major pharma and biotech companies. These are real workflows, not theoretical scenarios.
No data leaves the hospital. No individual patient predictions are returned. The entire compute pipeline runs inside the hospital's secure environment — your team receives aggregate statistics only.

A 30-minute call to discuss your therapeutic area, active programs, and whether our datasets fit your pipeline. No commitment, no generic pitch — just the disease groups, patient counts, and omics layers relevant to you.
Or email directly: info@tracebloc.io